Latest news items
April 23, 2013
Bayer CropScience and KeyGene announced that they have entered into a multi-year agreement to improve traits in a number of major agricultural crops. The scope of the first research program is wheat, potentially to be followed by programs in oilseed rape, rice and cotton. With their collaboration Bayer and KeyGene aim at contributing to a more efficient and sustainable wheat production. Financial details about the agreement were not disclosed.
April 8, 2013
Today the US based biotech company Kultevat and KeyGene, a biotech company from the Netherlands announced that they entered into collaboration for production of rubber based on the Russian dandelion. This plant has demonstrated potential as a domesticated crop for the U.S. and Europe; the origin of the species is the south eastern part of Kazachstan. Kultevat and KeyGene will invest in the development and commercial introduction of new dandelion varieties that are enriched for latex in its roots that are suitable for large scale production of natural rubber.
March 13, 2013
KeyGene announces today that it has further expanded its patent estate related to KeyPoint® Mutation Breeding (MB). Both the State Intellectual Property Office (SIPO) of the People’s Republic of China and the Australian Patent Office (IP Australia) granted KeyGene’s patent entitled "High Throughput Screening of Mutagenized Populations", which protectsmethodsfor detecting induced and natural genetic variation in large plant populations. These methodsform the cornerstone of KeyPoint MB programs, which deliver novel genetic variation in selected genesfortrait improvement in crops at industrialscale.
Febuari 14, 2013
Januari 31, 2013
November 05, 2012
Keygene N.V. and Floragenex Inc. announced today that they have entered into a license agreement in the field of Sequence Based Genotyping (SBG). The agreement includes dismissal of the patent infringement lawsuit filed by KeyGene in 2011 against Floragenex in the U.S. District Court for the District of Oregon. Under terms of the agreement, Floragenex will obtain a non-exclusive royalty bearing license to KeyGene’s intellectual property. Floragenex will continue to apply the Restriction-site Associated DNA (RAD) method in specified fields, including non-commercial and academic research in all species. The agreement strengthens the position of Floragenex as leader in RADseq applications and extends its portfolio of research service offerings. Financial terms were not disclosed.
August 27, 2012
Today, the Arizona Genome Institute (AGI) and KeyGene announced that they have entered into a broad license agreement that will enable AGI to market and execute sequence-based physical mapping projects using KeyGene’s proprietary Whole Genome Profiling (WGPTM) method.
August 10, 2012
Today, KeyGene announces that its Sequence-Based Genotyping (SBG) patent portfolio has been strengthened by the grant of European patent EP 2292788, entitled "Strategies for high throughput identification and detection of polymorphisms", protecting sequence-based detection of adapter-ligated restriction fragments. The patent is one of several patents and patent applications the company owns related to next-generation sequencing (NGS)-based detection of complexity-reduced DNA for genotyping purposes. The granted patent protects Complexity Reduction of Polymorphic Sequences (CRoPS®), SBG, the Restriction-site Associated DNA (RAD) technology and similar methods for random genetic marker detection encompassing complexity reduction, adapter ligation and sequencing.
May 30, 2012
Wageningen UR (University & Research centre) and KeyGene together with their partners in the Tomato Genome Consortium (TGC) have sequenced the genomes of the domesticated tomato and its wild ancestor, Solanum pimpinellifolium. This achievement is expected to lower costs and speed up efforts to improve the worldwide tomato production, making it better equipped to combat pests, pathogens, droughts and diseases that plague growers. The work may also speed up improvements to other crops. The sequences were reported in this week’s issue of Nature.
For more news items, visit the news archive.
PR & Corporate Communication
T +31 (0)317 466 866